V InterAmerican Oncology Conference: Current Status and Future of Anti-Cancer Targeted Therapies

InterAmerican Oncology Conferences
Last Modified: January 23, 2013

Dates: October 10-11, 2013
Location: Universidad Católica Argentina, Alicia M. de Justo 1680, Puerto Madero. Buenos Aires, Argentina

Sponsoring Group: InterAmerican Oncology Conferences

Web Page URL: www.oncologyconferences.com.ar

Topics Covered: The major emphasis will be on clinical aspects of cancer treatment in the 21st century with discussion of significant scientific advances underlying the novel approaches still in preclinical development.

Objectives: The meeting objectives are designed to introduce the audience to the latest information on targeted therapies, immunotherapies and emerging treatments in early development.

Who Should Attend: This meeting is the primary opportunity for hematologist, practicing oncologists, basic and clinical, scientists, translational investigators and health care workers to participate in a conference focusing on novel targeted therapies and other treatment advances which are changing the face of cancer care.

Agenda: The conference agenda will focus on new translational advances in the treatment of cancer as well as provide updates of conventional therapies for a number of the most common tumor types.

Registration Information:

Fees: The conference does not charge a registration fee

Continuing Education: No

Audience: HCP


7 Tips for Giving Smart on #givingtuesday
by Christina Bach, MSW, LCSW, OSW-C
November 25, 2015

Related News

RAD51 Mutations Confer Moderate Risk of Ovarian Cancer

Aug 16, 2015

RAD51C and RAD51D deleterious mutations linked to increased risk of epithelial ovarian cancer

Yoga May Help Maintain Quality of Life for Prostate Cancer Patients

Nov 22, 2015

Small study shows those undergoing radiation therapy had fewer side effects, less fatigue

AACR: Conference Offers Look at Cancer Drugs in Pipeline

Nov 28, 2015

International conference presentations include leukemia drug screening, olaparib, cediranib